Acute urinary retention associated with selective serotonin reuptake inhibitors and ziprasidone [4]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 5, 2007, Pages 517-519

  Chung, Albert K K ^a   Chua, Siew Eng ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CITALOPRAM; FLUOXETINE; LORAZEPAM; OLANZAPINE; SEROTONIN UPTAKE INHIBITOR; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; VENLAFAXINE; ZIPRASIDONE;

ADULT; ANAMNESIS; BALLOON CATHETER; BLOOD CELL COUNT; CASE REPORT; CATATONIC SCHIZOPHRENIA; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYNDROME; HOSPITAL ADMISSION; HUMAN; LETTER; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT RESPONSE; URINE RETENTION;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG MONITORING; ELECTROCONVULSIVE THERAPY; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; RECEPTORS, SEROTONIN, 5-HT2; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; THIAZOLES; URINARY CATHETERIZATION; URINARY RETENTION;

EID: 34548664608     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318150c80e     Document Type: Letter

References (19)

1. Beasley CM Jr, Sayler ME, Bosomworth JC, et al. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol. 1991;11(3):166-174.
2. British National Formulary. Selective serotonin reuptake-inhibitors. British Medical Association and Royal Pharmaceutical Society. 2005, March Chp 4.3.3. Available at: http://www.bnf.org/bnf/bnf/current/openat/index.htm. Accessed August 25, 2005.
3. Pfizer Inc. Geodon (Ziprasidone HCl) Manufacturer's information. 2005, May. Available at: http://www.pfizer.com/pfizer/download/uspi_geodon.pdf. Accessed August 25, 2005.
4. Seki S, Igawa Y, Kaidoh K, et al. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn. 2001;20:105-113.
5. Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology. 2003;62(suppl 4a):3-9.
6. Thor KB, Donatucci C. Central nervous system control of the lower urinary tract: new pharmacological approaches to stress urinary incontinence in women. J Urol. 2004;172(1): 27-33.
7. Cymbalta (Duloxetine) [package insert]. Indianapolis, IN: Eli Lilly and Company.
8. Burgard EC, Fraser MO, Thor KB. Serotonergic modulation of bladder afferent pathways. Urology. 2003;62(suppl 4A):10-15.
9. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005; 365:482-487.
10. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004;114:593-611.
11. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19): 6-12.
12. Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S] GTPgammaS binding study. Eur J Pharmacol. 1998;355(3):245-256.
13. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50:345-350.
14. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neruopsychopharmacol. 2001;25(6):871-880.
15. Schmidt AW, Lebel LA, Howard HR, et al. Ziprasidone: a novel anti-psychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197-201.
16. Vera PL, Miranda-Sousa A, Nadelhaft I. Effects of 2 atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats. BMC Pharmacol. 2001;1:4.
17. Benazzi F. Urinary retention with fluoxetine-haloperidol combination in a young patient. Can J Psychiatry. 1996;41:606-607.
18. Bozikas V, Petrikis P, Karavatos A. Urinary retention caused after fluoxetine-risperidone combination. J Psychopharmacol. 2001;15: 142-143.
19. Shiloh R, Weizman A, Dorfman-Etrog P, et al. Association between severity of schizophrenic symptoms and urinary retention. Eur Psychiatry. 2001;16:497-500.